Antithrombin nanoparticles inhibit stent thrombosis in ex vivo static and flow models.

Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection. Nat Commun (2016) 0.78

The Future of Nanoparticle-Directed Venous Therapy. Semin Intervent Radiol (2017) 0.75

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54

Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation (2001) 2.73

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation (2010) 2.27

Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc (2015) 1.24

Early atherosclerosis exhibits an enhanced procoagulant state. Circulation (2010) 1.14

Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des (2009) 1.13

Thrombin-inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis. J Thromb Haemost (2011) 1.06

Nox1 transactivation of epidermal growth factor receptor promotes N-cadherin shedding and smooth muscle cell migration. Cardiovasc Res (2011) 1.05

Endovascular intervention for peripheral artery disease. Circ Res (2015) 0.96

Surface modification of implanted cardiovascular metal stents: from antithrombosis and antirestenosis to endothelialization. J Biomed Mater Res A (2013) 0.94

Role of reactive oxygen species in inhibition of endothelial cell migration by oxidized low-density lipoprotein. J Vasc Surg (2004) 0.94

Bimodal concentration-dependent effect of thrombin on endothelial cell proliferation and growth factor release in culture. J Surg Res (2001) 0.91

Thrombin-targeted liposomes establish a sustained localized anticlotting barrier against acute thrombosis. Mol Pharm (2013) 0.90

Causes, assessment, and treatment of stent thrombosis--intravascular imaging insights. Nat Rev Cardiol (2015) 0.89

Thrombin-inhibiting nanoparticles rapidly constitute versatile and detectable anticlotting surfaces. Nanotechnology (2014) 0.84

Drug-eluting stents and balloons in peripheral arterial disease: evidence so far. Int J Clin Pract (2011) 0.84

Endothelial cells exhibit differential chemokinetic and mitogenic responsiveness to alpha-thrombin. J Surg Res (1997) 0.84

PAR-1 antagonists: current state of evidence. J Thromb Thrombolysis (2013) 0.83

Impact of bivalirudin and paclitaxel-eluting stents on outcomes in patients undergoing primary percutaneous coronary intervention of the left anterior descending artery. Am J Cardiol (2013) 0.79

In vitro study of thrombin on tubule formation and regulators of angiogenesis. Clin Appl Thromb Hemost (2010) 0.79